Literature DB >> 30019085

Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.

Simonetta Galgani1, Luca Prosperini2, Shalom Haggiag1, Carla Tortorella1, Claudio Gasperini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30019085     DOI： 10.1007/s00415-018-8976-7

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  8 in total

1.  Recognition of CD52 allelic gene products by CAMPATH-1H antibodies.

Authors:  C Hale; M Bartholomew; V Taylor; J Stables; P Topley; J Tite
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

2.  Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.

Authors:  Konstantina G Yiannopoulou; Dimitra Papadimitriou; Aikaterini I Anastasiou; Marina Siakantaris
Journal:  Mult Scler Relat Disord       Date:  2018-04-28       Impact factor: 4.339

Review 3.  Strategies in the management of alemtuzumab-related side effects.

Authors:  Anders Osterborg; Claes Karlsson; Jeanette Lundin; Eva Kimby; Håkan Mellstedt
Journal:  Semin Oncol       Date:  2006-04       Impact factor: 4.929

4.  Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.

Authors:  María Inés Gaitán; María Célica Ysrraelit; Jorge Correale
Journal:  JAMA Neurol       Date:  2017-09-01       Impact factor: 18.302

5.  Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.

Authors:  David Baker; Gavin Giovannoni; Klaus Schmierer
Journal:  Mult Scler Relat Disord       Date:  2017-09-25       Impact factor: 4.339

6.  Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab.

Authors:  Lyn R Ambrose; Anne-Sophie Morel; Anthony N Warrens
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

7.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Authors:  Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

8.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Authors:  Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321
  8 in total
  3 in total

1.  A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.

Authors:  A G Vakrakou; D Tzanetakos; S Valsami; E Grigoriou; K Psarra; J Tzartos; M Anagnostouli; E Andreadou; M E Evangelopoulos; G Koutsis; C Chrysovitsanou; E Gialafos; A Dimitrakopoulos; L Stefanis; C Kilidireas
Journal:  BMC Neurol       Date:  2018-10-29       Impact factor: 2.474

Review 2.  State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies.

Authors:  Emmanuel Andrès; Noel Lorenzo Villalba; Abrar-Ahmad Zulfiqar; Khalid Serraj; Rachel Mourot-Cottet; And Jacques-Eric Gottenberg
Journal:  J Clin Med       Date:  2019-09-01       Impact factor: 4.241

3.  Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis.

Authors:  Hans-Klaus Goischke
Journal:  Ther Clin Risk Manag       Date:  2019-07-12       Impact factor: 2.423
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.